JNJ-64164711  (Synonyms: JNJ-711)

JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated T cells and intratumoral regulatory T cells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors^[1].

Human

JNJ-64164711 binds human GITR with high affinity (K_d = 180 pM), interacts with human FcγRIIIa variants, targets the CRD1 domain of GITR, and does not inhibit GITR-GITRL binding^[1].
JNJ-64164711 mediates greater ADCC-driven depletion of GITR⁺ HuT102, KMS-12-BM, RPMI 8226, JJN-3 cell lines, primary activated GITR⁺ T cells, and in vitro expanded Tregs than other clinical-stage GITR agonist monoclonal antibodies^[1].
JNJ-64164711 selectively depletes intratumoral effector Tregs in dissociated primary human patient tumor samples^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

8784  [NCBI]

Q9Y5U5

TNFRSF18/GITR/CD357

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Holland C V, et al. Development of JNJ-64164711, a low fucose anti-GITR antibody for enhanced depletion of tumor regulatory T cells (Tregs)[J]. Cancer Research, 2018, 78(13_Supplement): 3813-3813.